Found: 78
Select item for more details and to access through your institution.
Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241260985
- By:
- Publication type:
- Article
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 558, doi. 10.1007/s10120-024-01466-w
- By:
- Publication type:
- Article
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241242607
- By:
- Publication type:
- Article
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02841-7
- By:
- Publication type:
- Article
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 4, p. 749, doi. 10.1002/ijc.34296
- By:
- Publication type:
- Article
Guest Editor.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 1, p. 6, doi. 10.1002/ijc.34341
- By:
- Publication type:
- Article
Current progress and advances in hepatocellular carcinoma: highlights from the 2022 ESMO annual meeting.
- Published in:
- Journal of Practical Oncology, 2023, v. 38, n. 1, p. 5, doi. 10.13267/j.cnki.syzlzz.2023.002
- By:
- Publication type:
- Article
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 1, p. 44, doi. 10.1159/000525499
- By:
- Publication type:
- Article
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
- Published in:
- British Journal of Cancer, 2022, v. 127, n. 12, p. 2241, doi. 10.1038/s41416-022-02001-3
- By:
- Publication type:
- Article
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
- Published in:
- Oncologist, 2022, v. 27, n. 12, p. e938, doi. 10.1093/oncolo/oyac183
- By:
- Publication type:
- Article
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using realworld data in third-line treatment of metastatic colorectal cancer.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1044328
- By:
- Publication type:
- Article
The In-Vitro Antitumor Effects of AST-3424 Monotherapy and Combination Therapy With Oxaliplatin or 5-Fluorouracil in Primary Liver Cancer.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.885139
- By:
- Publication type:
- Article
Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221090221
- By:
- Publication type:
- Article
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 24, p. 4585, doi. 10.1002/cncr.33870
- By:
- Publication type:
- Article
Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 11, p. 1944, doi. 10.1002/ijc.33751
- By:
- Publication type:
- Article
Icaritin-Induced FAM99A Affects GLUT1-Mediated Glycolysis via Regulating the JAK2/STAT3 Pathway in Hepatocellular Carcinoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.740557
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211039928
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. e1567, doi. 10.1002/onco.13826
- By:
- Publication type:
- Article
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 4439, doi. 10.2147/OTT.S307273
- By:
- Publication type:
- Article
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
- Published in:
- BioDrugs, 2021, v. 35, n. 4, p. 445, doi. 10.1007/s40259-021-00484-9
- By:
- Publication type:
- Article
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 296, doi. 10.1159/000513486
- By:
- Publication type:
- Article
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01095-1
- By:
- Publication type:
- Article
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
- Published in:
- Drug Design, Development & Therapy, 2021, v. 15, p. 1873, doi. 10.2147/DDDT.S304857
- By:
- Publication type:
- Article
The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 2, p. 153, doi. 10.1007/s11523-020-00787-x
- By:
- Publication type:
- Article
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211039928
- By:
- Publication type:
- Article
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
- Published in:
- Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 8, p. 1307, doi. 10.1111/jgh.14974
- By:
- Publication type:
- Article
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00886-2
- By:
- Publication type:
- Article
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00664
- By:
- Publication type:
- Article
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version).
- Published in:
- Chinese Journal of Lung Cancer, 2020, v. 23, n. 2, p. 65, doi. 10.3779/j.issn.1009-3419.2020.02.01
- By:
- Publication type:
- Article
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919889001
- By:
- Publication type:
- Article
Issue Cover.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. i, doi. 10.1111/liv.14277
- By:
- Publication type:
- Article
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2214, doi. 10.1111/liv.14223
- By:
- Publication type:
- Article
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. e702, doi. 10.1634/theoncologist.2018-0839
- By:
- Publication type:
- Article
Lung cancer with dermatomyositis as the initial diagnosis: A case report.
- Published in:
- Molecular & Clinical Oncology, 2019, v. 11, n. 1, p. 59, doi. 10.3892/mco.2019.1851
- By:
- Publication type:
- Article
A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix.
- Published in:
- OncoTargets & Therapy, 2019, v. 12, p. 5805, doi. 10.2147/OTT.S212536
- By:
- Publication type:
- Article
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.
- Published in:
- Oncology Letters, 2019, v. 17, n. 5, p. 4701
- By:
- Publication type:
- Article
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effects of UPF1 expression on EMT process by targeting E-cadherin, N-cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line.
- Published in:
- Molecular Medicine Reports, 2019, v. 19, n. 3, p. 2137
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
- Published in:
- Oncologist, 2019, v. 24, p. S3, doi. 10.1634/theoncologist.2019-IO-S1-s01
- By:
- Publication type:
- Article
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
- Published in:
- Neuroendocrinology, 2018, v. 107, n. 3, p. 237, doi. 10.1159/000491999
- By:
- Publication type:
- Article
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
- Published in:
- OncoTargets & Therapy, 2018, v. 11, p. 8565, doi. 10.2147/OTT.S161506
- By:
- Publication type:
- Article
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 9, p. 4570, doi. 10.1002/cam4.1664
- By:
- Publication type:
- Article
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China.
- Published in:
- Cost Effectiveness & Resource Allocation, 2018, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12962-018-0112-0
- By:
- Publication type:
- Article